{"protocolSection": {"identificationModule": {"nctId": "NCT02173548", "orgStudyIdInfo": {"id": "HM20000118"}, "secondaryIdInfos": [{"id": "1R34HL118348-01A1", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/1R34HL118348-01A1"}], "organization": {"fullName": "Virginia Commonwealth University", "class": "OTHER"}, "briefTitle": "Interleukin-1 Blockade in HF With Preserved EF", "officialTitle": "Interleukin-1 Blockade in Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Placebo-controlled Double Blinded Study (D-HART2)", "acronym": "D-HART2"}, "statusModule": {"statusVerifiedDate": "2018-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-09"}, "primaryCompletionDateStruct": {"date": "2017-04-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-06-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-06-20", "studyFirstSubmitQcDate": "2014-06-24", "studyFirstPostDateStruct": {"date": "2014-06-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-04-09", "resultsFirstSubmitQcDate": "2018-05-18", "resultsFirstPostDateStruct": {"date": "2018-06-19", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-05-18", "lastUpdatePostDateStruct": {"date": "2018-06-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Virginia Commonwealth University", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "* Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure\n* Standard treatment for heart failure, show less than ideal results in HFpEF\n* Evidence of systemic inflammation is common in all forms of heart failure, including HFpEF\n* The main hypothesis of this study is that systemic inflammation contributes to heart failure symptoms and exercise limitations in patients with HFpEF\n* The main objective is to treat patients with HFpEF and evidence of systemic inflammation with an anti-inflammatory drug targeting Interleukin-1 (or placebo) to determine effects on cardiovascular function", "detailedDescription": "Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure, characterized by symptoms of congestion and impaired exercise tolerance, secondary to impaired left ventricular filling (diastole) in absence of a significant impairment in contractility (LVEF\\>50%) or significant valvular abnormalities, shunts or intra- or extra-cavitary obstruction.\n\nThe standard treatment for patient with heart failure is very effective in Heart Failure with Reduced Ejection Fraction (HFrEF), but it not very effective in HFpEF.\n\nEvidence of systemic inflammation is common in all forms of heart failure, including HFpEF, and predicts worse outcomes. C reactive protein (CRP) is the preferred inflammatory biomarker used as risk predictor for cardiovascular disease. Patients with heart failure (HFpEF or HFrEF) with elevated CRP levels are more likely to be severely limited by heart failure symptoms, are more likely to be admitted to the hospital for heart failure, and are more likely to die of cardiac causes.\n\nPreclinical studies show that a key mediator of systemic inflammation, Interleukin-1 (IL-1), impairs cardiac and vascular function, and may contribute to the pathogenesis of heart failure.\n\nThe main hypothesis of this study is that systemic inflammation, and IL-1 in particular, contributes to heart failure symptoms and exercise limitations in patients with HFpEF.\n\nThe main objective is to treat patients with HFpEF and evidence of systemic inflammation with an IL-1 blocker, anakinra (recombinant human IL-1 receptor antagonist)(or placebo) to determine effects on exercise capacity measured as peak oxygen consumption at maximal cardiopulmonary exercise testing."}, "conditionsModule": {"conditions": ["Heart Failure With Normal Ejection Fraction"], "keywords": ["heart failure", "HFpEF", "diastole", "diastolic heart failure", "inflammation", "interleukin-1", "C-reactive protein"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 31, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Anakinra", "type": "ACTIVE_COMPARATOR", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks", "interventionNames": ["Drug: Anakinra"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Matching Placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Anakinra", "armGroupLabels": ["Anakinra"], "otherNames": ["Kineret"]}, {"type": "DRUG", "name": "Placebo", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Aerobic Exercise Capacity", "description": "Absolute changes in aerobic exercise capacity (peak VO2) after 12 weeks treatment. This will compare patients treated with anakinra and provide a randomized, double-blinded assessment of the effects of IL-1\u03b2 blockade on aerobic exercise performance.", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change in Ventilatory Eefficiency", "description": "Absolute changes in ventilatory efficiency (VE/VCO2 \\[carbon dioxide\\] slope) after 12 weeks treatment. This will compare patients treated with anakinra vs placebo, and provide a randomized, double-blinded assessment of the effects of IL-1\u03b2 blockade on aerobic exercise performance.", "timeFrame": "Baseline to 12 weeks"}], "secondaryOutcomes": [{"measure": "Echocardiographic Assessment of Diastolic and Systolic Function (Left Ventricular Ejection Fraction)", "description": "Structural and functional echocardiographic parameters include left and right ventricular dimensions, mass, systolic and diastolic function. (Change in e')", "timeFrame": "12 weeks"}, {"measure": "Change in Diastolic and Contractile Reserve (e' Velocity and E/e' Ratio)", "description": "Exercise stress echocardiography will be performed at baseline and 12 weeks to measure diastolic and contractile reserve. We will perform an assessment before initiation of exercise and immediately after cessation of peak exercise.", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change in Inflammation (C Reactive Protein Levels)", "description": "The change C reactive protein (CRP) levels will be reported at 12 weeks. Higher C reactive protein levels indicate greater inflammation.", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Change in Quality of Life Questionnaire-Minnesota Living With Heart Failure Questionnaire (MLWHF)", "description": "The Minnesota Living with Heart Failure questionnaire (MLWHF) is a 21-question graded questionnaire that has been extensively used to measure impairment in quality of life in patients with HF, with higher scores reflecting increased burden of HF symptoms. The questionnaire will be administered in accordance with cardiopulmonary test (CPET) and echocardiography. Scores range from zero to 105 with lower scores indicating better quality of life.", "timeFrame": "Baseline to 24 weeks"}, {"measure": "Change in Quality of Life Questionnaire-Duke Activity Status Index (DASI)", "description": "Two independent questionnaires will be used to assess quality of life and HF symptoms. The Duke Activity Status Index (DASI) questionnaire is a 12-question, yes/no, instrument that allows for the calculation of perceived functional capacity, in which each question describes a different physical activity and the questions are weighted according to their degree of physical exertion. Higher scores indicate greater functional capacity. The questionnaire will be administered at 0, 4, 12 and 24 weeks in accordance with cardiopulmonary test (CPET) and echocardiography. Scores range from zero to 58.2 with higher scores indicating higher functional status.", "timeFrame": "Baseline to 12 weeks"}, {"measure": "Hospital Admission for Acute Decompensated Heart Failure", "description": "Number of participants admitted to hospital for acute decompensated heart failure", "timeFrame": "24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Symptoms and signs of heart failure (NYHA II-III) and prior hospitalization for heart failure\n2. Recent Imaging Study (\\<12 months) showing LVEF\\>50% and Left Ventricular End Diastolic Volume Index (LVEDVI) \\<97ml/m2\n3. Evidence of abnormal LV relaxation, filling, diastolic distensibility, and diastolic stiffness as shown by one of the following\n\n   a. Invasive Hemodynamic measurements i. mean Pulmonary Capillary Wedge Pressure (mPCW) \\>12 ii. Left Ventricular End Diastolic Pressure (LVEDP) \\>16 mmHg b. Tissue Doppler Echocardiogram i. E/E' \\>15 ii. E/E' 8-15 and one of the following: Left Ventricular Hypertrophy (LVH), Atrial fibrillation, Left Atrial Enlargement (LAE), E/A \\<0.5 + DT (Deceleration Time) \\>280, c. Biomarkers i. Brain Natriuretic Peptide (BNP) \\>200pg/ml (not due to a concomitant disease such as pulmonary arterial hypertension, pulmonary embolism, acute renal failure, or other)\n4. CRP \\> 2.0 mg/L\n\nExclusion Criteria:\n\n* Age \\<21\n* Concomitant conditions or treatments which would affect completion of the study or interpretation of the study tests including but not limited to the following conditions:\n\n  * physical inability to walk or run on a treadmill\n  * angina or evidence of spontaneous or inducible ischemia\n  * uncontrolled arterial hypertension\n  * atrial fibrillation (or other arrhythmias)\n  * moderate to severe valvular heart disease\n  * chronic pulmonary disease\n  * anemia (Hgb\\<10 g/dl)\n* Angina, uncontrolled hypertension or electrocardiograph (ECG) changes (i.e. ischemia, arrhythmias) that limit maximum exertion during cardiopulmonary exercise testing\n* Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable cardioverter defibrillator (AICD) or coronary revascularization or cardiac surgery\n* Active infection including chronic infection\n* Active cancer (or prior diagnosis of cancer within the past 10 years)\n* Recent (\\<14 days) or active use of immunosuppressive drugs (including but not limited to high-dose corticosteroids \\[\\>1_mg/kg of prednisone equivalent\\], Tumor Necrosis Factor (TNF)-\u03b1 blockers, cyclosporine) not including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or corticosteroids used for IV dye allergy only)\n* Chronic auto-immune or auto-inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus)\n* Neutropenia (absolute neutrophil count\\<1,800/mm3 \\[or \\<1,000/mm3 in African-American patients\\])\n* Severe impairment in renal function (estimated glomerular filtration rate \\<30 ml/kg\\*min)\n* Recent or planned use of vaccination with live attenuated viruses\n* Allergy to rubber or latex\n* Allergy to products derived from Escherichia coli\n* Pregnancy or breastfeeding\n* Inability to give informed consent", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Antonio Abbate, MD, PhD", "affiliation": "Virginia Commonwealth University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Benjamin Van Tassell, PharmD", "affiliation": "Virginia Commonwealth University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Virginia Commonwealth University", "city": "Richmond", "state": "Virginia", "zip": "23298", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}]}, "referencesModule": {"references": [{"pmid": "30354558", "type": "DERIVED", "citation": "Van Tassell BW, Trankle CR, Canada JM, Carbone S, Buckley L, Kadariya D, Del Buono MG, Billingsley H, Wohlford G, Viscusi M, Oddi-Erdle C, Abouzaki NA, Dixon D, Biondi-Zoccai G, Arena R, Abbate A. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2018 Aug;11(8):e005036. doi: 10.1161/CIRCHEARTFAILURE.118.005036."}, {"pmid": "28475816", "type": "DERIVED", "citation": "Van Tassell BW, Buckley LF, Carbone S, Trankle CR, Canada JM, Dixon DL, Abouzaki N, Oddi-Erdle C, Biondi-Zoccai G, Arena R, Abbate A. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin Cardiol. 2017 Sep;40(9):626-632. doi: 10.1002/clc.22719. Epub 2017 May 5."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra"}, {"id": "FG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra"}, {"id": "BG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "31"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "31"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "18"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "15"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "16"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "28"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Aerobic Exercise Capacity", "description": "Absolute changes in aerobic exercise capacity (peak VO2) after 12 weeks treatment. This will compare patients treated with anakinra and provide a randomized, double-blinded assessment of the effects of IL-1\u03b2 blockade on aerobic exercise performance.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "ml/kg/min", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "lowerLimit": "-0.9", "upperLimit": "1.7"}, {"groupId": "OG001", "value": "1.0", "lowerLimit": "-1.3", "upperLimit": "2.0"}]}]}]}, {"type": "PRIMARY", "title": "Change in Ventilatory Eefficiency", "description": "Absolute changes in ventilatory efficiency (VE/VCO2 \\[carbon dioxide\\] slope) after 12 weeks treatment. This will compare patients treated with anakinra vs placebo, and provide a randomized, double-blinded assessment of the effects of IL-1\u03b2 blockade on aerobic exercise performance.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "VE/VO2 slope", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "lowerLimit": "-2.1", "upperLimit": "1.8"}, {"groupId": "OG001", "value": "-0.2", "lowerLimit": "-1.6", "upperLimit": "1.3"}]}]}]}, {"type": "SECONDARY", "title": "Echocardiographic Assessment of Diastolic and Systolic Function (Left Ventricular Ejection Fraction)", "description": "Structural and functional echocardiographic parameters include left and right ventricular dimensions, mass, systolic and diastolic function. (Change in e')", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "cm/second", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "lowerLimit": "-0.8", "upperLimit": "1.0"}, {"groupId": "OG001", "value": "1.9", "lowerLimit": "-0.3", "upperLimit": "4.0"}]}]}]}, {"type": "SECONDARY", "title": "Change in Diastolic and Contractile Reserve (e' Velocity and E/e' Ratio)", "description": "Exercise stress echocardiography will be performed at baseline and 12 weeks to measure diastolic and contractile reserve. We will perform an assessment before initiation of exercise and immediately after cessation of peak exercise.", "populationDescription": "Data not available for all participants.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "ratio", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "lowerLimit": "-5.7", "upperLimit": "3.1"}, {"groupId": "OG001", "value": "0.7", "lowerLimit": "-4.5", "upperLimit": "0.7"}]}]}]}, {"type": "SECONDARY", "title": "Change in Inflammation (C Reactive Protein Levels)", "description": "The change C reactive protein (CRP) levels will be reported at 12 weeks. Higher C reactive protein levels indicate greater inflammation.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mg/l", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.8", "lowerLimit": "-7.5", "upperLimit": "-0.5"}, {"groupId": "OG001", "value": "1.2", "lowerLimit": "-1.2", "upperLimit": "2.4"}]}]}]}, {"type": "SECONDARY", "title": "Change in Quality of Life Questionnaire-Minnesota Living With Heart Failure Questionnaire (MLWHF)", "description": "The Minnesota Living with Heart Failure questionnaire (MLWHF) is a 21-question graded questionnaire that has been extensively used to measure impairment in quality of life in patients with HF, with higher scores reflecting increased burden of HF symptoms. The questionnaire will be administered in accordance with cardiopulmonary test (CPET) and echocardiography. Scores range from zero to 105 with lower scores indicating better quality of life.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "units on MWLHF scale", "timeFrame": "Baseline to 24 weeks", "groups": [{"id": "OG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6", "lowerLimit": "-19", "upperLimit": "1"}, {"groupId": "OG001", "value": "-16", "lowerLimit": "-24", "upperLimit": "-11"}]}]}]}, {"type": "SECONDARY", "title": "Change in Quality of Life Questionnaire-Duke Activity Status Index (DASI)", "description": "Two independent questionnaires will be used to assess quality of life and HF symptoms. The Duke Activity Status Index (DASI) questionnaire is a 12-question, yes/no, instrument that allows for the calculation of perceived functional capacity, in which each question describes a different physical activity and the questions are weighted according to their degree of physical exertion. Higher scores indicate greater functional capacity. The questionnaire will be administered at 0, 4, 12 and 24 weeks in accordance with cardiopulmonary test (CPET) and echocardiography. Scores range from zero to 58.2 with higher scores indicating higher functional status.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "units on DASI scale", "timeFrame": "Baseline to 12 weeks", "groups": [{"id": "OG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4", "lowerLimit": "-2.5", "upperLimit": "12.6"}, {"groupId": "OG001", "value": "6.5", "lowerLimit": "-6.6", "upperLimit": "11.4"}]}]}]}, {"type": "SECONDARY", "title": "Hospital Admission for Acute Decompensated Heart Failure", "description": "Number of participants admitted to hospital for acute decompensated heart failure", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "24 weeks", "description": "One participant in the anakinra arm withdrew from the study before receiving any study-related interventions.", "eventGroups": [{"id": "EG000", "title": "Anakinra", "description": "Anakinra 100 mg given subcutaneously once daily for 12 weeks\n\nAnakinra", "deathsNumAffected": 0, "deathsNumAtRisk": 20, "seriousNumAffected": 1, "seriousNumAtRisk": 20, "otherNumAffected": 4, "otherNumAtRisk": 20}, {"id": "EG001", "title": "Placebo", "description": "Matching Placebo\n\nPlacebo", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 1, "seriousNumAtRisk": 10, "otherNumAffected": 2, "otherNumAtRisk": 10}], "seriousEvents": [{"term": "Acute decompensated heart failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 10}]}], "otherEvents": [{"term": "Upper respiratory infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 10}]}, {"term": "Non serious infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 20}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 10}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Antonio Abbate, MD, PhD", "organization": "Virginia Commonwealth University", "email": "antonio.abbate@vcuhealth.org", "phone": "(804) 828-0513"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2016-04-20", "uploadDate": "2018-02-21T08:55", "filename": "Prot_SAP_000.pdf", "size": 1710650}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10293", "name": "Inflammation", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000053590", "term": "Interleukin 1 Receptor Antagonist Protein"}], "ancestors": [{"id": "D000018501", "term": "Antirheumatic Agents"}], "browseLeaves": [{"id": "M27359", "name": "Interleukin 1 Receptor Antagonist Protein", "asFound": "Constipation", "relevance": "HIGH"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}